Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ERBB3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
ERBB3 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Latest Hotspot
8 min read
FGFR4 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
FGFR4 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Latest Hotspot
8 min read
FGFR1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
FGFR1 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Pharma Frontiers
8 min read
CDK6 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
CDK6 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Pharma Frontiers
8 min read
BIRC5 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
BIRC5 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Latest Hotspot
8 min read
HSP90AA1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
HSP90AA1 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Latest Hotspot
8 min read
MAPK1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
MAPK1 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Latest Hotspot
8 min read
MAP2K1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
MAP2K1 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Latest Hotspot
8 min read
AKT1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
AKT1 target evaluation report generated with PatSnap Life Sciences MCP data, covering biology, validation evidence, competition, IP and R&D strategy.
Latest Hotspot
8 min read
TREM2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
This TREM2 Target Evaluation Report is generated from PatSnap MCP data. TREM2 has an appealing macrophage-reprogramming idea, but the clinical record is thin and both retrieved solid-tumor trials were terminated. This should be read as a cautious target, not a validated opportunity.
Latest Hotspot
8 min read
ENPP1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
This ENPP1 Target Evaluation Report is generated from PatSnap MCP data. ENPP1 is a readable immuno-oncology target because it connects tumor cGAMP degradation to STING-pathway suppression. The current clinical story is early but strategically coherent.
Latest Hotspot
8 min read
DHODH Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
This DHODH Target Evaluation Report is generated from PatSnap MCP data. DHODH has a clear differentiation rationale in AML, but the clinical record is mixed. The readable conclusion is cautious: biology is interesting, yet several programs were terminated or withdrawn.